CHINA RESOURCES BOYA BIO-PHARMACEUTICAL GROUP CO.,LTD Financials China Resources Boya Bio-pharmaceutical Group Co.,Ltd
Equities
300294
CNE100001FF1
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.28 CNY | -0.29% |
|
-1.14% | -7.13% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,302 | 14,286 | 19,338 | 18,435 | 16,983 | 15,773 | - | - |
| Enterprise Value (EV) 1 | 13,302 | 14,286 | 19,338 | 18,435 | 16,983 | 15,773 | 15,773 | 15,773 |
| P/E ratio | 31.2 x | 55 x | 48.5 x | 42.5 x | 71.7 x | 28.8 x | 26.2 x | 23.3 x |
| Yield | 0.48% | 0.19% | - | 0.55% | 0.89% | 0.99% | 1.12% | 0.48% |
| Capitalization / Revenue | 4.57 x | 5.32 x | 7.3 x | 6.68 x | 6.4 x | 8.26 x | 7.59 x | 6.89 x |
| EV / Revenue | 4.57 x | 5.32 x | 7.3 x | 6.68 x | 6.4 x | 8.26 x | 7.59 x | 6.89 x |
| EV / EBITDA | 21.9 x | 33.5 x | - | - | 36.5 x | 19.5 x | 19.9 x | 18.5 x |
| EV / FCF | -6,67,24,642 x | - | - | - | 3,04,63,248 x | - | - | - |
| FCF Yield | -0% | - | - | - | 0% | - | - | - |
| Price to Book | 3.46 x | 3.54 x | 2.87 x | 2.57 x | 2.32 x | 2.04 x | 1.93 x | 1.79 x |
| Nbr of stocks (in thousands) | 4,25,940 | 4,25,940 | 5,04,249 | 5,04,249 | 5,04,249 | 5,04,249 | - | - |
| Reference price 2 | 31.23 | 33.54 | 38.35 | 36.56 | 33.68 | 31.28 | 31.28 | 31.28 |
| Announcement Date | 28/02/20 | 26/04/21 | 22/03/22 | 12/03/23 | 13/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,909 | 2,684 | 2,651 | 2,759 | 2,652 | 1,909 | 2,077 | 2,288 |
| EBITDA 1 | 608.1 | 426.1 | - | - | 465.6 | 807 | 791 | 853 |
| EBIT 1 | 514.1 | 331.5 | 443.1 | 532.2 | 355.2 | 731 | 748.2 | 816.7 |
| Operating Margin | 17.67% | 12.35% | 16.72% | 19.29% | 13.39% | 38.3% | 36.03% | 35.69% |
| Earnings before Tax (EBT) 1 | 520 | 328.1 | 443.1 | 532 | 353.7 | 733 | 747 | 816 |
| Net income 1 | 426.1 | 260.1 | 344.5 | 432.2 | 237.5 | 548.8 | 602.6 | 675 |
| Net margin | 14.65% | 9.69% | 13% | 15.67% | 8.95% | 28.75% | 29.01% | 29.5% |
| EPS 2 | 1.000 | 0.6100 | 0.7900 | 0.8600 | 0.4700 | 1.088 | 1.195 | 1.340 |
| Free Cash Flow | -199.4 | - | - | - | 557.5 | - | - | - |
| FCF margin | -6.85% | - | - | - | 21.02% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | 119.75% | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | 234.77% | - | - | - |
| Dividend per Share 2 | 0.1500 | 0.0650 | - | 0.2000 | 0.3000 | 0.3100 | 0.3500 | 0.1500 |
| Announcement Date | 28/02/20 | 26/04/21 | 22/03/22 | 12/03/23 | 13/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 734.9 | 649.5 | 461.6 | 448.5 | 573 | 507 | 360 | 710 | 648 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | 170.3 | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS | 0.3400 | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 24/04/23 | 21/08/23 | 25/10/23 | 13/03/24 | 23/04/24 | - | - | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -199 | - | - | - | 557 | - | - | - |
| ROE (net income / shareholders' equity) | 11.4% | 6.49% | 7.83% | 6.18% | 3.28% | 7.35% | 7.66% | 8.1% |
| ROA (Net income/ Total Assets) | - | 4.99% | - | 5.52% | - | 6.92% | 7.26% | 7.63% |
| Assets 1 | - | 5,207 | - | 7,828 | - | 7,931 | 8,300 | 8,852 |
| Book Value Per Share 2 | 9.030 | 9.480 | 13.30 | 14.30 | 14.50 | 15.30 | 16.20 | 17.50 |
| Cash Flow per Share 2 | -0.2600 | 1.660 | 3.080 | 1.180 | 1.270 | 1.600 | 1.240 | 1.390 |
| Capex 1 | 84.8 | 141 | - | 138 | 84.2 | 160 | 192 | 227 |
| Capex / Sales | 2.92% | 5.25% | - | 5.01% | 3.18% | 8.4% | 9.24% | 9.93% |
| Announcement Date | 28/02/20 | 26/04/21 | 22/03/22 | 12/03/23 | 13/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.28
CNY
Average target price
34.45
CNY
Spread / Average Target
+10.12%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.13% | 2.18B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 300294 Stock
- Financials China Resources Boya Bio-pharmaceutical Group Co.,Ltd
